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Abstract
Background: Allergic	diseases	 (eczema,	wheeze	and	 rhinitis)	 in	children	often	pre‐
sent	as	heterogeneous	phenotypes.	Understanding	genetic	associations	of	specific	
patterns	 of	 symptoms	 might	 facilitate	 understanding	 of	 the	 underlying	 biological	
mechanisms.
Objective: To	examine	associations	between	allergic	disease‐related	variants	identi‐
fied	in	a	recent	genome‐wide	association	study	and	latent	classes	of	allergic	diseases	
(LCADs)	in	two	population‐based	birth	cohorts.
Methods: Eight	previously	defined	LCADs	between	birth	and	11	years:	“No	disease,”	
“Atopic	march,”	“Persistent	eczema	and	wheeze,”	“Persistent	eczema	with	later‐onset	
rhinitis,”	 “Persistent	wheeze	with	 later‐onset	rhinitis,”	 “Transient	wheeze,”	“Eczema	
only”	and	“Rhinitis	only”	were	used	as	the	study	outcome.	Weighted	multinomial	lo‐
gistic	regression	was	used	to	estimate	associations	between	135	SNPs	(and	a	poly‐
genic	risk	score,	PRS)	and	LCADs	among	6345	individuals	from	The	Avon	Longitudinal	
Study	of	Parents	and	Children	(ALSPAC).	Heterogeneity	across	LCADs	was	assessed	
before	 and	 after	 Bonferroni	 correction.	 Results	 were	 replicated	 in	 Manchester	
Asthma	and	Allergy	Study	(MAAS)	(n	=	896)	and	pooled	in	a	meta‐analysis.
Results: We	found	strong	evidence	 for	differential	genetic	associations	across	 the	
LCADs;	pooled	PRS	heterogeneity	P‐value	=	3.3	×	10−14,	excluding	“no	disease”	class.	
The	associations	between	the	PRS	and	LCADs	in	MAAS	were	remarkably	similar	to	
ALSPAC.	Two	SNPs	(a	protein‐truncating	variant	in	FLG	and	a	SNP	within	an	intron	of	
GSDMB)	had	evidence	for	differential	association	(pooled	P‐values	≤	0.006).	The	FLG 
locus	was	differentially	associated	across	LCADs	that	included	eczema,	with	stronger	
associations	for	LCADs	with	comorbid	wheeze	and	rhinitis.	The	GSDMB	locus	in	con‐
trast	was	equally	associated	across	LCADs	that	included	wheeze.
Conclusions and clinical relevance: We	have	shown	complex,	but	distinct	patterns	
of	 genetic	 associations	 with	 LCADs,	 suggesting	 that	 heterogeneous	 mechanisms	
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1  | INTRODUC TION
Although	asthma,	eczema	(atopic	dermatitis)	and	allergic	rhinitis	(AR)	
are	 diagnosed	 clinically	 as	 distinct	 conditions,	 their	 co‐occurrence	
is	well	 acknowledged.1	 Twin	heritability	 estimates	 vary	 vastly,	 the	
range	has	been	reported	to	be	between	35%	and	95%	for	asthma,	
33%	and	91%	for	AR	and	71%	and	84%	for	eczema,2	and	estimates	
of	the	genetic	correlation	between	them	are	also	high:	0.55	between	
asthma	and	eczema,	0.47	between	asthma	and	rhinitis	and	0.62	be‐
tween	eczema	and	rhinitis.3	This	supports	shared	genetic	factors	be‐
tween	all	three	conditions,	but	also	genetic	factors	that	are	specific	
to	each.	Although	we	are	starting	to	uncover	both	shared	and	specific	
genetic	risk	factors,	understanding	more	precisely	which	loci	predis‐
pose	individuals	to	particular	patterns	of	symptoms	should	translate	
into	 clinical	 benefits,	 such	 as	 personalized	 approaches	 to	 disease	
management	and	identification	of	novel	therapeutic	targets.4
Children	often	present	with	broad	and	heterogeneous	phenotypes	
of	allergic	diseases.5,6	For	example,	some	cases	have	mild	symptoms	
affecting	a	single	organ/system,	but	others	have	more	severe	symp‐
toms	encompassing	multiple	organs	(eg	skin,	upper	and	lower	airways).	
The	term	“atopic	march”	has	been	proposed	for	a	specific	pattern	of	
progression	 from	childhood	eczema	to	subsequent	asthma	and	AR.7 
We	have	previously	used	Bayesian	machine	learning	methods	to	model	
the	developmental	profiles	of	eczema,	wheeze	and	rhinitis	during	child‐
hood	 in	 two	 population‐based	 birth	 cohorts:	 the	Avon	 Longitudinal	
Study	of	Parent	and	Children	(ALSPAC)	and	the	Manchester	Asthma	
and	Allergy	Study	(MAAS).8	Eight	latent	classes	were	identified,	each	
characterized	by	unique	patterns	of	diseases	over	time:	“No	disease”	
(51.3%	of	the	children),	“Atopic	march”	(3.1%),	“Persistent	eczema	and	
wheeze”	 (2.7%),	 “Persistent	 eczema	with	 later‐onset	 rhinitis”	 (4.7%),	
“Persistent	wheeze	with	later‐onset	rhinitis”	(5.7%),	“Transient	wheeze”	
(7.7%),	“Eczema	only”	(15.3%)	and	“Rhinitis	only”	(9.6%).
A	recent	genome	wide	association	study	(GWAS)9	identified	136	
independent	risk	variants	(P	<	3	×	10−8)	for	asthma,	eczema	and	AR,	
including	73	novel	variants,	and	went	on	 to	 link	 the	pathophysiol‐
ogy	 of	 allergic	 diseases	 to	 132	 neighbouring	 genes.	Although	 this	
study	was	designed	to	detect	risk	variants	shared	across	allergic	dis‐
eases,	six	SNPs	in	five	established	risk	loci	(rs61816761,	rs921650,	
rs115288876,	rs12470864,	rs6594499	and	rs61839660)	were	iden‐
tified	as	having	some	disease‐specific	effects.	In	this	study,	we	aimed	
to	examine	the	associations	between	these	136	genetic	variants	as‐
sociated	with	 allergic	 diseases9	 and	 the	 developmental	 profiles	 of	
eczema,	wheeze,	and	rhinitis	(“Latent	Classes	of	Allergic	Diseases”,	
LCADs)	we	previously	described8	to	better	understand	the	genetic	
heterogeneity	between	the	allergic	disease	class	profiles.
2  | METHODS
2.1 | Study populations
Avon	 Longitudinal	 Study	 of	 Parents	 and	Children	 is	 a	 population‐
based	 birth	 cohort	which	 recruited	 14	 541	 pregnant	women	with	
expected	delivery	dates	between	1st	April	1991	and	31st	December	
1992.	The	study	protocol	was	described	previously.10,11	Ethical	ap‐
proval	was	obtained	 from	the	ALSPAC	Ethics	and	Law	Committee	
and	 local	 research	ethics	 committees.	The	 study	website	 contains	
details	of	all	 the	data	 that	are	available	 through	a	 fully	 searchable	
data	 dictionary:	 http://www.bris.ac.uk/alspa	c/resea	rcher	s/data‐
acces	s/data‐dicti	onary/	.
Manchester	Asthma	and	Allergy	Study	is	an	unselected	birth	co‐
hort	established	in	1995	in	Manchester.12	It	included	1184	children	
born	between	February	1996	and	April	1998.	Participants	were	re‐
cruited	prenatally	and	followed	prospectively.13	The	study	was	ap‐
proved	by	the	Local	Research	Ethics	Committee.
2.2 | Latent classes of allergic diseases (LCADs)
Eight	LCADs	were	previously	identified	using	a	latent	disease	profile	
model	in	a	Bayesian	machine	learning	modelling	framework	applied	
to	 longitudinal	 individual	 reports	 of	 eczema,	 wheezing	 and	 rhini‐
tis	 collected	at	multiple	 time	points	between	ages	1	and	11	years	
using	 joint	 ALSPAC	 and	 MAAS	 data8,14:	 “No	 disease”,	 “Atopic	
march,”	 “Persistent	 eczema	 and	wheeze,”	 “Persistent	 eczema	with	
later‐onset	 rhinitis”,	 “Persistent	 wheeze	 with	 later‐onset	 rhinitis,”	
“Transient	 wheeze,”	 “Eczema	 only,”	 “Rhinitis	 only”;	 these	 are	 de‐
scribed	in	more	detail	in	the	Supplemental	Material.	Posterior	prob‐
abilities	of	class	membership	(mean	probabilities	between	0.76	and	
0.94	in	joint	ALSPAC	and	MAAS	data)	were	used	as	the	outcome	in	
this	study	(Table	S2	in	Belgrave	et	al8).
2.3 | Genotyping
In	 ALSPAC,	 we	 used	 the	 Illumina	 HumanHap550	 quad	 chip	 and	
imputed	 against	 the	Dec	 2013	Version	 1	 Phase	 3	 release	 of	 1000	
Genomes	reference	haplotypes15	using	IMPUTE2.16	Participants	with	
genetic	 evidence	 of	 non‐European	 ancestry	were	 excluded	 before	
underlie	individual	disease	trajectories.	Establishing	the	combination	of	allergic	dis‐
eases	with	which	each	genetic	variant	is	associated	may	inform	therapeutic	develop‐
ment	and/or	predictive	modelling.
K E Y W O R D S
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rhinitis
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imputation.	Further	details	describing	the	QC	and	imputation	proce‐
dure	of	the	ALSPAC	genetic	data	can	be	found	here.17	In	MAAS,	DNA	
samples	were	genotyped	using	Illumina	610	quad	and	imputed	using	
the	1000	Genomes	Phase	3	integrated	variant	set	reference.18
2.3.1 | Genetic risk score
Per‐allele	SNP	dosages	were	extracted	in	ALSPAC	for	the	136	SNPs	
identified	 in	previous	GWAS,9	and	proxies	were	 identified	for	SNPs	
with	 imputation	 quality	 <	 0.80	 (Table	 S1).	 All	 136	 relevant	 SNPs	
were	available;	SNP	rs34290285	was	excluded	due	to	poor	imputa‐
tion	quality	and	lack	of	adequate	proxy.	All	135	SNPs	included	in	the	
ALSPAC	score	were	available	in	MAAS;	SNP	rs10305290	was	mono‐
morphic	and	hence	excluded	from	the	MAAS	score	(see	Supplemental	
Material).	A	weighted	polygenic	risk	score	(PRS)	including	135	SNPs	
with	INFO	≥0.77	was	derived,	weighted	according	to	the	overall	ef‐
fect	 sizes	 observed	 in	 Ref.	 9.	 The	 standardized	 PRS	 represented	 a	
per	1‐standard	deviation	increase	in	the	weighted	risk	score	(details	
in	Supplemental	Material).	Individual	SNPs	were	also	analysed	sepa‐
rately,	where	each	SNP	was	coded	as	 the	dosage	of	 the	 risk	 allele.	
Following	 investigation	 of	 individual	 SNPs,	 a	 modified	 PRS,	 which	
excluded	 any	 SNPs	 with	 evidence	 for	 differential	 association,	 was	
generated	to	test	for	any	residual	effects	among	the	remaining	SNPs.
2.4 | Association analysis
For	the	PRS	and	each	SNP,	a	multinomial	logistic	regression	was	con‐
ducted,	and	relative	risk	ratios	(RRR;	also	known	as	multinomial	odd	
ratio)	with	corresponding	95%	confidence	intervals	(Cis)	for	associa‐
tions	of	the	PRS	or	SNP	dosages	with	the	LCADs	were	reported.	All	
regressions	 were	 weighted	 by	 posterior	 membership	 probabilities	
(the	probabilities	that	a	child	belongs	to	each	class)	 to	account	for	
uncertainty	in	class	membership.	“No	disease”	class	was	used	as	the	
baseline	group.
Heterogeneity	P‐values	from	chi‐square	tests	excluding	(degrees	
of	freedom	=	6)	and	including	(degrees	of	freedom	=	7)	the	“No	dis‐
ease”	class	were	generated	(using	post‐estimation	test	command)	to	
test	 for	both	associations	with	any	 latent	class	and	differential	as‐
sociations	across	LCADs.	To	further	assess	heterogeneity,	pairwise	
tests	among	disease	 latent	classes	were	performed	when	omnibus	
test	for	differential	associations	provided	nominal	evidence	for	over‐
all	heterogeneity.
In	 the	 single	 SNP	 analysis,	 a	 Bonferroni‐corrected	 P‐value 
threshold	was	calculated	 (P	=	 .05/135	=	3.7	×	10−4)	 to	 control	 for	
type	 1	 error.	 For	 six	 SNPs	 reported	 as	 disease‐specific	 in	 GWAS	
(rs61816761,	 rs921650,	 rs115288876,	 rs12470864,	 rs6594499	
and	rs61839660),9	a	 less	stringent	p‐value	threshold	of	8.3	×	10−3 
(0.05/6)	was	also	used.
To	 assess	 the	 level	 of	 power	 in	 the	 analysis	 of	 ALSPAC	 data,	
power	calculations	were	conducted	for	associations	with	individual	
phenotypes	(details	in	the	Supplemental	Material	and	Table	S2).
The	 associations	 of	 the	 nominal	 SNPs	 (P	 	 <	 .05)	 identified	 in	
ALSPAC	and	the	genetic	risk	scores	(original	and	modified	versions)	
with	LCADs	were	then	tested	in	MAAS.	Pooled	estimates	and	overall	
test	for	heterogeneity	between	sub‐groups	(including	and	excluding	
“No	disease”	class)	were	derived.	All	statistical	analyses	were	con‐
ducted	with	Stata	15.0.19
3  | RESULTS
3.1 | Characteristics of the study populations
A	total	of	6345	participants	in	ALSPAC	and	896	in	MAAS	had	both	
genetic	and	outcome	data.	Characteristics	of	the	study	populations	
are	presented	in	Table	1.
Similar	proportions	of	males	 (51.1%,	53.8%),	 lower	social	class	
(43.9%,	36.9%)	and	lower	maternal	educational	level	(57.5%,	55.3%)	
were	reported	in	ALSPAC	and	MAAS,	respectively	(for	more	details	
see	Supplemental	Material).	Parents	of	participants	excluded	from	
the	study	because	of	missing	data	tended	to	be	from	the	lower	so‐
cial	 class	 (P	 =	 3.54	×	10−29)	 and	 lower	maternal	 educational	 level	
(P	=	1.31	×	10−62)	in	ALSPAC,	as	seen	before.20	Marginal	evidence	
for	lower	social	class	among	the	excluded	individual	was	observed	
in	 MAAS	 (P	 =	 .10),	 but	 not	 for	 lower	 maternal	 educational	 level	
(P	=	.39).	No	differences	were	found	between	proportions	of	LCADs	
in	the	study	populations	vs.	the	excluded	samples	in	either	cohort	
(Table	1).
3.2 | Discovery population (ALSPAC)
3.2.1 | Standardized genetic score (original)
There	was	strong	evidence	for	an	association	between	the	standard‐
ized	PRS	and	the	LCADs	(het.	P‐value	=	3.2	×	10−30	including	“No	dis‐
ease”	class)	and	strong	evidence	for	differential	association	with	the	
PRS	across	the	latent	classes	(het	P‐value	=	3.3	×	10−13	excluding	“No	
disease”	 class),	with	 stronger	 associations	 observed	 for	 classes	with	
more	than	one	disease	(Figure	1	and	Table	S3).	Pairwise	tests	provide	
further	evidence	for	differential	associations	between	multiple‐disease	
and	single‐disease	classes:	P‐values	≤	9.68	×	10−10	for	“atopic	march”	vs	
“transient	wheeze,”	“eczema	only”	and	“rhinitis	only”	(Table	S4).
3.2.2 | Individual SNP associations
Table	S5	reports	 individual	associations	for	all	135	 individual	SNPs	
with	 LCADs.	 Two	 SNPs,	 rs61816761	 (a	 protein‐truncating	 variant	
in FLG)	 and	 rs921650	 (within	an	 intron	of	GSDMB),	 showed	strong	
evidence	 for	differential	 association	between	 the	LCADs	 (P‐values	
0.002	 and	 1.42	 ×	 10−5,	 respectively,	 excluding	 “No	 disease”	 class)	
(Table	S5	and	Figures	2	and	3).	Pairwise	 tests	provide	 further	evi‐
dence	 of	 these	 differential	 associations:	P‐values	 ≤	 8.8	 ×	 10−3	 for	
“transient	wheeze”	vs	“persistent	eczema	LO	rhinitis”,	“eczema	only”	
and	“rhinitis	only”	in	the	association	between	rs921650	(GSDMB)	and	
the	LCADs;	P‐values	≤	3.0	×	10−3	for	“atopic	march”	vs.	“persistent	
wheeze	LO	rhinitis,”	“transient	wheeze”	and	“rhinitis	only”	in	the	as‐
sociations	between	rs61816761	(FLG)	and	the	LCADs	(Table	S6).
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Characteristics
Study sampled
Excluded sample (no 
data on outcome and/or 
genetics)
P‐valuec
N with char‐
acteristic (%) Total N
N with char‐
acteristic (%) Total N
ALSPAC
Gender	(male) 3244	(51.1) 6345 4375	(51.6) 8479 0.575
Lower	combined	
social	classa
2617	(43.9) 5957 3017	(54.4) 5547 3.54E‐29
Lower	maternal	edu‐
cational	levelb
3577	(57.5) 6220 4466	(71.8) 6218 1.31E‐62
Allergic	diseases	latent	classese
No	Disease 3175	(50.0) 6345 1150	(49.8) 2309 (Reference)
Atopic	March 175	(2.8) 59	(2.5) 0.621
Persistent	eczema	
and	wheeze
181	(2.9) 72	(3.1) 0.508
Persistent	eczema	
with	late‐onset	
rhinitis
307	(4.8) 111	(4.8) 0.991
Persistent	wheeze	
with	late‐onset	
rhinitis
348	(5.5) 149	(6.5) 0.107
Transient	wheeze 534	(8.4) 195	(8.4) 0.939
Eczema	only 948	(15.0) 323	(14.0) 0.394
Rhinitis	only 677	(10.7) 250	(10.8) 0.820
MAAS
Gender	(male) 482	(53.8) 896 186	(55.7) 287 0.305
Lower	combined	
social	classa
225	(36.9) 610 60	(43.2) 139 0.101
Lower	maternal	edu‐
cational	levelb
359	(55.3) 649 45	(57.7) 78 0.392
Allergic	diseases	latent	classese
No	Disease 322	(35.9) 896 87	(38.9) 223 (reference)
Atopic	March 55	(6.1) 11	(5.1) 0.471
Persistent	eczema	
and	wheeze
46	(5.1) 10	(4.6) 0.611
Persistent	eczema	
with	late‐onset	
rhinitis
73	(8.1) 18	(7.9) 0.710
Persistent	wheeze	
with	late‐onset	
rhinitis
81	(9.0) 18	(8.2) 0.557
Transient	wheeze 65	(7.3) 15	(6.8) 0.644
Eczema	only 141	(15.7) 34	(15.3) 0.634
Rhinitis	only 114	(12.8) 29	(13.1) 0.836
aMother	and	partner	level	of	occupation	(manual	vs	non‐manual)	in	ALSPAC,	combined	socio‐eco‐
nomic	status	(not	working,	routine,	intermediate	vs	managerial)	in	MAAS.	
bIn	ALSPAC,	mother	educated	to	the	General	Certificate	of	Education	level	(school‐leaving	certif‐
icate)	or	lower;	In	MAAS,	mother	not	educated	to	UK	A	or	As	level	(data	from	follow‐up	question‐
naire	at	13‐16	y).	
cP‐values	are	from	chi‐squared	test	for	binary	variables	and	logistic	regression	for	latent	variables	
(baseline	group	is	“no	disease”	class),	comparing	“included”	vs	“excluded”	individuals.	
dParticipants	with	SNP	data	and	outcome	data	available.	
eProportions	were	weighted	by	posterior	membership	probabilities.	
TA B L E  1  Characteristics	of	the	
study	populations	in	ALSPAC	and	MAAS	
cohorts
     |  5CLARK et AL.
A	modified	 PRS	 which	 excluded	 these	 two	 SNPs	 still	 showed	
strong	 evidence	 for	 differential	 association	 (heterogeneity	 P‐
value	=	9.6	×	10−12,	 Table	 S3;	 Figure	4),	 suggesting	 that	 there	 are	
additional	differential	 associations	 among	 the	SNPs	which	did	not	
meet	our	significance	threshold.
Four	 additional	 SNPs	 (rs11652139,	 rs479844,	 rs6990534	 and	
rs5743618)	 showed	 nominal	 evidence	 of	 differential	 association	
across	the	LCADs	(heterogeneity	P‐values	<	.05,	Table	S5).	Pairwise	
tests	provide	further	evidence	of	these	differential	associations.	For	
example:	P‐values	≤	6.8	×	10−3	for	“eczema	only”	vs	“atopic	march,”	
“persistent	 wheeze	 LO	 rhinitis”	 and	 “transient	 wheeze”	 in	 the	
association	between	rs11652139	and	the	LCADs;	P‐values	≤	 .007	
for	“atopic	march”	vs	“transient	wheeze”	and	“eczema	only”	in	the	
association	between	rs6990534	and	the	LCADs	(Table	S6).
3.3 | Replication in MAAS and Pooled Estimates
3.3.1 | Standardized genetic scores (original and 
modified)
The	 associations	 between	 the	PRS	 and	 LCADs	 in	MAAS	were	 re‐
markably	similar	to	ALSPAC	(Table	S7	and	Figure	1).	 In	the	pooled	
F I G U R E  1  Forest	plot	of	the	associations	between	the	standardized	genetic	score	and	allergic	disease	latent	classes	in	ALSPAC	and	
MAAS	cohorts
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analysis,	 there	 was	 strong	 evidence	 for	 differential	 association	
across	LCADs	(excluding	the	baseline	class;	P‐value	=	3.27	×	10−14).	
To	 investigate	 the	 nature	 of	 these	 differences,	we	 compared	ORs	
and	 CIs	 across	 the	 seven	 classes.	 There	was	 evidence	 for	 a	 large	
effect	 on	 “Atopic	 march”	 (pooled	 RRR	 =	 1.99,	 95%	 CI	 1.74‐2.29),	
“Persistent	 eczema	 with	 late‐onset	 rhinitis”	 (1.51,	 1.35‐1.68),	
“Persistent	 wheeze	 with	 late‐onset	 rhinitis”	 (1.44,	 1.30‐1.60)	 and	
“Persistent	eczema	and	wheeze”	(1.39,	1.22‐1.60),	per	1‐SD	increase	
in	 the	 per‐risk‐allele	 standardized	 PRS	 compared	 to	 “No	 disease”.	
A	modest	 increased	 risk	was	observed	 for	 LCADs	affecting	 single	
organ/system:	 “Transient	wheeze”	 (1.11,	1.02‐1.21),	 “Eczema	only”	
(1.16,	 1.08‐1.24)	 and	 “Rhinitis	 only”	 (1.21,	 1.12‐1.31),	 per	 unit	 in‐
crease	in	the	PRS	compared	to	“No	disease”	class	(Table	2;	Figure	1).
Omitting	SNPs	rs61816761	(a	protein‐truncating	variant	in	FLG)	
and	rs921650	(within	an	 intron	of	GSDMB)	 from	original	standard‐
ized	PRS	slightly	attenuated	the	associations	across	LCADs	(pooled	
het.	P‐value	=	3.83	×	10−12	including	“No	disease,”	1.07	×	10−12 ex‐
cluding	“No	disease”	class)	(Table	2;	Figure	4).
F I G U R E  2  Forest	plot	of	the	associations	between	SNP	rs61816761[A]	near	Filaggrin	gene	and	allergic	disease	latent	classes	in	ALSPAC	
and	MAAS	cohorts
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3.3.2 | Individual SNP associations
We	tested	six	nominally	associated	individual	SNPs	from	ALSPAC	
(P	<	.05)	in	MAAS	(Table	S8).	Pooled	results	are	shown	in	Table	3.	
We	found	moderate	evidence	for	differential	associations	across	
LCADs	 (excluding	 the	 baseline	 class)	 for	 SNPs	 rs61816761,	
rs921650	and	rs11652139	(pooled	heterogeneity	P‐values	≤	.006).	
To	investigate	the	nature	of	these	differences,	we	compared	ORs	
and	CIs	 across	 the	7	 LCADs.	There	was	 evidence	 for	 a	 large	 ef‐
fect	 on	 “Atopic	 march”	 (pooled	 RRR	 =	 3.01,	 95%CI	 1.79‐5.08),	
“Persistent	 eczema	 and	 wheeze”	 (1.87,	 1.01‐3.48),	 “Persistent	
eczema	 with	 late‐onset	 rhinitis”	 (2.30,	 1.45‐3.65)	 and	 “Eczema	
only”	 (1.63,	 1.15‐2.30),	 per	 increased	 A‐allele	 of	 rs61816761	 (a	
protein‐truncating	variant	 in	FLG)	 (Table	3;	Figure	2).	Little	or	no	
evidence	of	association	was	seen	for	other	LCADs.	We	found	evi‐
dence	 for	 a	 large	 effect	 on	 “Atopic	march”	 (pooled	 RRR	 =	 1.36,	
95%CI	 1.13‐1.65),	 “Persistent	 eczema	 and	 wheeze”	 (1.37,	
1.13‐1.66),	 “Persistent	 wheeze	 with	 late‐onset	 rhinitis”	 (1.36,	
1.18‐1.57)	and	“Transient	wheeze”	(1.24,	1.10‐1.40),	per	increased	
A‐allele	 of	 rs921650	 (within	 an	 intron	 of	GSDMB),	 compared	 to	
“No	disease”	(Table	3;	Figure	3).	Little	or	no	evidence	of	associa‐
tion	was	seen	for	other	LCADs.
F I G U R E  3  Forest	plot	of	the	associations	between	SNP	rs921650[A]	near	GSDMB	gene	and	allergic	disease	latent	classes	in	ALSPAC	and	
MAAS	cohorts
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The	pattern	of	associations	for	SNP	rs11652139	was	very	sim‐
ilar	 to	SNP	rs921650	 (within	an	 intron	of	GSDMB)	 (Table	3;	Figure	
S1).	For	SNP	rs479844,	we	found	evidence	for	a	moderate	effect	on	
“Persistent	eczema	with	late‐onset	rhinitis”	(pooled	RRR	1.21,	95%	
CI	1.04‐1.41)	and	“Eczema	only”	(1.14,	1.03‐1.26)	per	increased	G‐al‐
lele,	when	compared	to	“No	disease”	class	(Figure	S2).	We	observed	
evidence	for	a	moderate	effect	on	“Atopic	march”	per	increased	A‐al‐
lele	of	SNP	rs6990534	(1.33,	1.09‐1.62)	(Figure	S3)	and	per	increased	
C‐allele	of	SNP	rs5743618	(1.31,	1.04‐1.67);	SNP	rs5743618	showed	
evidence	 for	a	moderate	effect	on	 “Rhinitis	only”	 (1.19,	1.04‐1.36)	
(Figure	S4).
4  | DISCUSSION
We	examined	the	associations	between	135	 independent	 risk	vari‐
ants	 for	 allergic	 diseases	 identified	 in	 a	 recent	GWAS9	 and	LCADs	
which	we	previously	 described	 in	 two	 independent	birth	 cohorts.8 
SNP	rs61816761	(a	protein‐truncating	variant	in	FLG	gene)	and	SNP	
rs921650	(within	an	intron	of	GSDMB)	which	were	previously	identi‐
fied	as	having	disease‐specific	effects9	were	differentially	associated	
with	distinct	LCADs.	The	FLG	locus	was	associated	with	all	LCADs	that	
included	eczema,	with	 stronger	associations	 seen	 for	 those	classes	
with	comorbid	wheeze	and/or	rhinitis.	In	contrast,	the	strength	of	the	
F I G U R E  4  Forest	plot	of	the	associations	between	the	modified	standardized	genetic	score	(excluding	SNPs	rs61816761	and	rs921650)	
and	allergic	disease	latent	classes	in	ALSPAC	and	MAAS	cohorts
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association	for	GSDMB	locus	was	equal	for	all	LCADs	which	included	
wheeze,	with	no	 additional	 risk	 for	 comorbid	 eczema	 and/or	 rhini‐
tis.	An	 allergic	 disease	polygenic	 risk	 score	 (including	 all	 135	SNPs	
and	after	excluding	SNPs	rs61816761	and	rs921650)	showed	strong	
evidence	of	 heterogeneity	 across	 the	 LCADs,	 suggesting	 there	 are	
further	individual	SNPs	with	differential	association.
4.1 | rs61816761 (FLG)
rs61816761	 (also	 known	 as	R501X)	 has	 long	 been	 linked	with	 ec‐
zema.21	In	Ferreira's	GWAS,9	the	risk	allele	[A]	for	SNP	rs61816761,	
which	 is	 located	on	chromosome	1	 in	the	FLG	gene,	was	1.32‐fold	
more	 common	 in	 individuals	 experiencing	 eczema‐only	 symptoms	
Allergic diseases latent classes
ALSPAC‐MAAS pooled multinomial odds ratio 
(95% CI)
Stand. Score
Stand. Score excluding 
FLG and GSDMB SNPs
Atopic	March 1.99	(1.74,2.29) 1.90	(1.66,2.18)
Persistent	eczema	and	wheeze 1.39	(1.22,1.60) 1.35	(1.17,1.54)
Persistent	eczema	with	late‐onset	
rhinitis
1.51	(1.35,1.68) 1.49	(1.34,1.66)
Persistent	wheeze	with	late‐onset	
rhinitis
1.44	(1.30,1.60) 1.42	(1.28,1.57)
Transient	wheeze 1.11	(1.02,1.21) 1.09	(1.00,1.19)
Eczema	only 1.16	(1.08,1.24) 1.15	(1.07,1.23)
Rhinitis	only 1.21	(1.12,1.31) 1.21	(1.12,1.31)
P‐value	for	differential	associationa 3.27E‐14 1.07E‐12
P‐value	for	any	associationb 1.22E‐13 3.83E‐12
aOverall	test	for	heterogeneity	between	classes	excluding	the	baseline	class	of	“no	disease”.	
bOverall	test	for	heterogeneity	between	classes	including	the	baseline	class	of	“no	disease”	(Pooled	
multinomial	Odds	Ratio	=	1).	
TA B L E  2  ALSPAC‐MAAS	pooled	
estimates	of	the	associations	between	
standardized	genetic	scores	and	profile	
latent	classes	before	and	after	excluding	
SNPs	rs61816761	(FLG)	and	rs921650	
(GSDMB)
TA B L E  3  ALSPAC‐MAAS	pooled	estimates	of	the	associations	between	the	top	six	nominal	SNPs	(heterogeneity	p‐value	excluding	the	
baseline	“no	disease”	class	<	0.05)	and	allergic	diseases	latent	classes
SNP[RA]
ALSPAC‐MAAS pooled multinomial odds ratio (95% CI)
rs61816761[A] rs921650[A]
rs11652139[A] rs479844[G] rs6990534[A] rs5743618[C]Nearby Gene FLG GSDMB
Allergic	diseases	latent	classes
Atopic	March 3.01	(1.79,5.08) 1.36	(1.13,1.65) 1.47	(1.20,1.80) 1.12	(0.92,1.36) 1.33	(1.09,1.62) 1.31	(1.04,1.67)
Persistent	eczema	
and	wheeze
1.87	(1.01,3.48) 1.37	(1.13,1.66) 1.22	(1.00,1.49) 1.19	(0.98,1.44) 0.92	(0.74,1.14) 0.98	(0.78,1.22)
Persistent	eczema	
with	late‐onset	
rhinitis
2.30	(1.45,3.65) 0.95	(0.82,1.11) 1.06	(0.91,1.24) 1.21	(1.04,1.41) 1.08	(0.91,1.27) 1.06	(0.89,	1.26)
Persistent	wheeze	
with	late‐onset	
rhinitis
0.87	(0.47,1.62) 1.36	(1.18,1.57) 1.22	(1.05,1.42) 0.95	(0.82,1.10) 1.03(0.88,1.21) 1.13	(0.96,1.35)
Transient	wheeze 1.00	(0.60,1.66) 1.24	(1.10,1.40) 1.15	(1.02,1.31) 1.02	(0.90,1.16) 0.93	(0.81,1.07) 0.97	(0.84,	1.13)
Eczema	only 1.63	(1.15,2.30) 0.99	(0.90,1.09) 0.98	(0.88,1.08) 1.14	(1.03,1.26) 0.96	(0.86,1.07) 0.99	(0.89,	1.11)
Rhinitis	only 1.08	(0.69,1.68) 1.00	(0.90,1.12) 1.04	(0.93,1.17) 0.95	(0.85,1.06) 1.10	(0.98,1.24) 1.19	(1.04,	1.36)
P‐value	for	differen‐
tial	associationa 
0.006 1.71E‐05 0.006 0.044 0.055 0.138
P‐value	for	any	
associationb 
0.011 4.26E‐05 0.011 0.074 0.091 0.207
Abbreviation:	RA,	risk	allele.
aOverall	test	for	heterogeneity	between	classes	excluding	the	baseline	class	of	“no	disease”.	
bOverall	test	for	heterogeneity	between	classes	including	the	baseline	class	of	“no	disease”	(Pooled	multinomial	Odds	Ratio	=	1).	
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compared	with	 individuals	experiencing	only	AR.	Similarly,	a	1.26‐
fold	 difference	was	 observed	when	 comparing	 individuals	 experi‐
encing	only	eczema	with	individuals	with	only	asthma.	This	indicated	
that	this	SNP	predisposes	to	eczema	more	strongly	than	to	either	of	
the	other	two	conditions.	In	the	present	study,	we	found	evidence	
for	a	large	effect	on	each	of	the	four	latent	classes	including	eczema,	
but	no	association	with	classes	which	did	not	 include	eczema.	We	
observed	the	strongest	association	with	“Atopic	march”	(pooled	RRR	
3.01).	 This	 is	 in	 line	with	 a	 recent	meta‐analysis	which	 found	 that	
the	two	FLG	mutations	combined	(R501X	and	FLG	2282del4)	were	
associated	with	Atopic	march.22
It	 is	 tempting	 to	 speculate	 that	 genotyping	 patients	 with	 ec‐
zema	for	FLG	mutations	could	help	to	identify	individuals	who	may	
benefit	from	interventions	targeted	at	prevention	of	progression	to	
the	atopic	march.23	However,	 the	difference	 in	odds	between	 the	
“Atopic	march”	versus	“Eczema	only”	classes	is	of	insufficient	mag‐
nitude	to	be	of	a	clinical	predictive	value.	It	is	also	important	to	note	
that	whilst	FLG	mutations	 (including	R501X)	 play	 a	 role	 in	 predis‐
posing	individuals	of	Caucasian	ancestry	to	eczema,	such	mutations	
have	not	been	seen	in	other	ethnic	groups.24
4.2 | rs921650 (GSDMB)
In	Ferreira's	GWAS,9	the	risk	allele	[A]	for	SNP	rs921650	on	chro‐
mosome	 17q21.1	 was	 1.08‐fold	 more	 common	 in	 asthma‐only	
compared	with	eczema‐only	cases.	It	was	also	1.04‐fold	more	com‐
mon	in	asthma‐only	compared	with	AR‐only	cases,	thus	represent‐
ing	a	stronger	risk	factor	for	asthma	compared	with	both	eczema	
and	AR.	 In	 the	 present	 study,	we	 found	 evidence	 for	 a	 large	 ef‐
fect	 on	 all	 four	wheeze‐related	 classes	 per	 increased	 A‐allele	 of	
rs921650.	However,	unlike	for	associations	with	FLG	locus,	where	
we	 observed	 increasing	 odds	 for	 classes	 with	 comorbid	 wheeze	
and	 rhinitis	 (ORs	 from	1.87	 to	3.01)	when	compared	 to	 “Eczema	
only”	class	 (OR	1.63),	 for	associations	with	GSDMB	 locus,	we	did	
not	 observe	 increasing	 odds	 for	 classes	 with	 comorbid	 eczema	
and	rhinitis	(ORs	from	1.36	to	1.37),	when	compared	to	“Transient	
wheeze”	class	(OR	1.24).	These	results	suggest	that	there	is	no	ad‐
ditional	risk	of	comorbid	conditions	compared	to	wheeze	alone	in	
association	with	GSDMB.
rs921650	 is	 located	within	 an	 intron	 of	GSDMB	 (gasdermin	B)	
gene	(also	known	as	GSDML),25,26	likely	affecting	the	expression	of	
genes	 in	 the	17q21	 locus.	 SNPs	 in	 the	17q21	 locus	have	been	as‐
sociated	 with	 childhood	 asthma,	 and	 there	 is	 evidence	 that	 com‐
mon	SNPs	 in	 this	 region	 are	 associated	with	 persistent	wheeze.27 
Results	of	our	analysis	 are	consistent	with	 this	evidence,	with	 the	
increased	risk	of	three	classes	characterized	by	wheeze	persistence	
(“Persistent	wheeze	with	late‐onset	rhinitis,”	“Persistent	eczema	and	
wheeze”	 and	 “Atopic	 march”)	 per	 increased	 A‐allele	 of	 rs921650.	
Our	study	has	also	shown	evidence	for	an	association	of	rs921650	
with	transient	wheeze	when	defined	as	high	probability	of	wheeze	
within	the	first	5 years,	with	remission	by	age	8 years,	and	a	very	low	
probability	of	eczema	and	rhinitis	throughout	childhood.	Given	that	
early‐life	wheeze	 in	 the	 absence	of	 other	 allergic	 symptoms	 (such	
as	 eczema)	 is	 mostly	 virus‐induced,	 our	 results	 are	 in	 agreement	
with	observations	from	recent	studies	which	provided	evidence	that	
polymorphisms	on	chromosome	17q21	regulate	ICAM1	expression	
and	thus	may	affect	the	frequency	and	severity	of	rhinovirus	infec‐
tion	and	early	childhood	wheezing	illness,28	that	impaired	anti‐virus	
immunity	is	associated	with	early‐life	wheezing,29	and	that	early‐life	
antibiotic	use	(a	proxy	for	impaired	innate	anti‐virus	immunity)	is	as‐
sociated	with	17q21	polymorphisms.30
4.3 | Interpretation of the Polygenic Risk Score 
(PRS)
We	report	strong	evidence	of	heterogeneity	of	associations	across	
the	 LCADs	 (pooled	 het.	P‐value	 =	 3.3	 ×	 10−14	 excluding	 “No	 dis‐
ease”	class).	The	strongest	association	was	seen	for	“Atopic	march”	
(pooled	 RRR	 1.99,	 1.74‐2.29).	 Our	 results	 suggest	 that	 although	
the	presence	of	multiple	 risk	alleles	 increases	the	risk	of	all	 latent	
classes,	 this	 is	 strongest	 for	 the	 “Atopic	march,”	 and	weakest	 for	
the	classes	characterized	by	the	presence	of	single	symptoms.	This	
may	indicate	that	the	greater	the	standardized	per‐allele	weighted	
PRS,	 the	 greater	 the	 likelihood	 of	 developing	multiple	 comorbidi‐
ties.	 After	 excluding	 SNPs	 rs61816761	 and	 rs921650,	 this	 effect	
was	 still	observed	 (pooled	het.	P‐value	=	1.1	×	10−12).	As	none	of	
these	 133	 individual	 SNPs	 showed	 good	 evidence	 for	 differential	
association,	 we	 can	 assume	 that	 there	 are	 some	 unidentified	 dif‐
ferential	single	SNP	associations,	which	we	did	not	have	power	to	
detect.	Therefore,	studies	of	larger	sample	sizes	should	be	designed	
to	investigate	this	further.
4.4 | Strengths and Limitations
The	prevalence	of	rhinitis‐related	classes	was	higher	in	MAAS	com‐
pared	to	ALSPAC.8	However,	in	the	original	study,	similar	latent	pro‐
files	were	 identified	 in	MAAS	 and	ALSPAC,	 suggesting	 consistent	
patterns	across	 the	 two	populations.8	 Furthermore,	we	have	used	
latent	 classes	 derived	 from	 joint	 modelling,	 which	 accounted	 for	
these	differences	and	increased	the	resolution	of	the	identified	la‐
tent	classes.8
The	restricted	sample	(after	removal	of	individuals	who	had	miss‐
ing	genetic	and/or	outcome	data)	 resulted	 in	a	 loss	of	participants	
from	 lower	 social	 class	 and	 maternal	 educational	 level.	 Selection	
bias	 can	 be	 introduced	 if	 the	 individuals	 from	 a	 lower	 social	 class	
had	missing	data	because	of	factors	related	to	the	outcome.	Issues	
such	as	 this	 can	 also	 impact	on	 the	generalizability	of	 the	 results.	
However,	 despite	 the	 loss	 of	 individuals	 from	 lower	 social	 class,	
there	was	still	a	good	representation	in	the	included	study	samples	
(43.9%	in	ALSPAC	and	36.9%	in	MAAS).
Avon	 Longitudinal	 Study	 of	 Parents	 and	 Children	 was	 part	 of	
the	 meta‐analysis	 by	 Ferreira	 et	 al	 that	 was	 used	 to	 identify	 the	
136	SNPs;	 this	 could	have	 led	 to	 some	overfitting	 in	our	ALSPAC	
analysis.	However,	 our	 sample	 only	makes	 up	 0.6%	of	 the	 sample	
used	by	Ferreira	et	al	and	our	main	analysis	focuses	on	the	compar‐
ison	between	case	(disease)	groups,	rather	than	the	comparison	of	
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combined	cases	versus	controls	 (from	which	 the	beta	values	were	
taken)	so	any	overfitting	is	likely	to	be	negligible.
It	is	likely	that	combining	the	SNPs	in	a	composite	score	increased	
the	power	sufficiently	to	detect	an	overall	effect,	even	when	indi‐
vidual	SNPs	showed	little	evidence	of	association.	However,	group‐
ing	together	variants	which	may	individually	have	different	effects	
might	act	to	attenuate	or	obscure	individual	effects.
Whilst	understanding	more	about	the	role	that	the	135	genetic	
variants	 identified	 to	date	by	Ferreira	et	 al	play	 in	allergic	disease	
profiles	is	beneficial,	a	 limitation	of	the	Ferreira	approach	is	that	 it	
is	better	powered	to	detect	homogenous	as	opposed	to	heteroge‐
neous	effects	 and	 so	 there	may	be	 additional	 SNPs	with	 interest‐
ing	heterogeneous	effects	that	have	yet	to	be	identified.	However,	
our	results	are	a	good	proof	of	principle	of	the	latent	disease	profile	
method	as	a	good	way	to	characterize	heterogenous	effects	across	
the	allergic	disease	classes.	As	carefully	phenotyped	GWAS	sample	
sizes	 increase,	 it	may	be	possible	to	undertake	such	 latent	disease	
profile	 analyses	 in	 a	 GWAS	 context	 with	 better	 power	 to	 detect	
novel	loci	with	heterogenous	effects.
4.5 | Conclusions
We	 found	 strong	 evidence	 for	 differential	 genetic	 associations	
across	 different	 developmental	 profiles	 of	 eczema,	 wheeze	 and	
rhinitis,	 which	 were	 remarkably	 consistent	 across	 two	 cohorts.	
Two	polymorphisms	(a	protein‐truncating	variant	in	FLG	and	a	SNP	
within	an	intron	of	GSDMB)	showed	evidence	for	distinct	patterns	
of	association.	The	FLG	locus	was	associated	with	all	profiles	that	
included	 eczema,	 but	 with	 stronger	 associations	 for	 those	 with	
comorbid	 wheeze	 and/or	 rhinitis.	 The	 GSDMB	 locus	 in	 contrast	
was	 associated	 with	 all	 profiles	 which	 included	 wheeze	 (includ‐
ing	wheezing	up	to	age	5 years	with	remission	by	age	8 years),	but	
with	 no	 additional	 risk	 of	 comorbid	 conditions.	 This	 emphasizes	
the	 likely	 complex	 and	 heterogeneous	 mechanisms	 underlying	
within‐individual	disease	trajectories	and	demonstrates	the	need	
for	future	studies	to	take	account	of	the	complex	nature	of	these	
associations.	 Our	 analysis	 using	 a	 PRS	 also	 demonstrates	 that	
there	 is	 likely	 to	be	additional	heterogeneity	among	other	SNPs,	
that	this	study	did	not	have	power	to	detect.	This	approach	to	dis‐
entangling	the	complex	nature	of	multi‐trait	aetiology	might	be	a	
promising	one	that	should	be	used	in	future	larger	studies.
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